Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9295308 | 0.95 | SCN3A (0.51) | SCN3ADPP7LMNAALDH1A1KDM4E | |
| SCHEMBL23440919 | 0.86 | SCN3A (0.68) | SCN3ASPHK2SPHK1 | |
| SCHEMBL1202552 | 0.82 | HTT (0.61) | DPP7LMNAALDH1A1KDM4ECHRM2 | |
| SCHEMBL11273783 | 0.82 | CA2 (0.55) | SCN3ASPHK2SPHK1CYP3A4 | |
| SCHEMBL4462532 | 0.81 | KDM4E (0.55) | ALDH1A1KDM4EDPP4 | |
| SCHEMBL19624194 | 0.81 | DPP7 (0.53) | DPP7LMNAALDH1A1KDM4ECHRM2 | |
| SCHEMBL840310 | 0.81 | MEN1 (0.50) | SCN3ASPHK2SPHK1CYP2D6CYP2C19 | |
| SCHEMBL8338352 | 0.81 | CYP2C9 (0.61) | SCN3AALDH1A1SPHK2SPHK1CHRM2 | |
| SCHEMBL8340797 | 0.81 | KMT2A (0.51) | SCN3ALMNAALDH1A1KDM4ESPHK2 | |
| SCHEMBL9903661 | 0.80 | SCN3A (0.48) | SCN3AALDH1A1SPHK2SPHK1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | claimed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | claimed |
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | disclosed |
| EP-2460798-A2 | APAF-1 INHIBITOR COMPOUNDS | Laboratorios SALVAT, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | PCNA, MCL1, MYC | SCN3A 3888/4885DPP7 4007/4885LMNA 2699/4885 |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | SCN3A 2811/4885DPP7 251/4885LMNA 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.